NOVO NORDISK SHARES TUMBLE AFTER 2030 GOALS SET OUT
Novo Nordisk shares tumbled on Monday after the Ozempic maker set out its goals for 2030, reports said. Investors had been hoping for concrete turnaround plans from Chief Executive Mike Doustdar, but the announcement did not deliver them.
According to reports, Novo Nordisk has lost its lead in the obesity drug market to Eli Lilly & Co.
← BACK